Skip to main content
Premium Trial:

Request an Annual Quote

Tepnel Raises $2.25M in Stock Offering to Help Pay for Scottish Consolidation

NEW YORK, June 2 (GenomeWeb News) - Tepnel Life Sciences has raised £1.2 million ($2.3 million) in a stock offering, the UK-based company said today.

The funds will be used as "working capital" and also to complete the company's new 18,000-square-foot facility in Livingston, Scotland. The new facility will consolidate operations in Edinburgh and Glasgow and incorporate pharmaceutical services including high throughput genotyping and protein analysis.

The company placed 17,034,160 new ordinary shares priced at 7p apiece with institutional shareholders. In addition, the company has given its investors warrantes to buy as many as 4.3 million additional shares. Tepnel expects stands to gain approximately £340,000 if all the shares are purchased in the warrant.

Tepnel applied to have the shares available for trading on the London Stock Exchange's AIM market on June 6.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.